Clinical Trial Update: Safety and Efficacy of Lorbrena

View source ↗

Summary

Pfizer's clinical trial update reports safety and efficacy data for lorlatinib (Lorbrena) in non-small cell lung cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lorbrena (lorlatinib)

Snippet

Sponsor: Pfizer | Conditions: Non-small Cell Lung Cancer | Status: COMPLETED